🚀 VC round data is live in beta, check it out!
Longeveron Valuation Multiples
Discover revenue and EBITDA valuation multiples for Longeveron and similar public comparables like BioXcel Therapeutics, Tvardi Therapeutics, Lipum, Outlook Therapeutics and more.
Longeveron Overview
About Longeveron
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer’s disease (AD) and Aging-related Frailty.
Founded
2014
HQ
Employees
26
Website
Sectors
Financials (LTM)
EV
$28M
Longeveron Financials
Longeveron reported last 12-month revenue of $1M.
In the same LTM period, Longeveron generated $755K in gross profit and had net loss of ($24M).
Revenue (LTM)
Longeveron P&L
In the most recent fiscal year, Longeveron reported revenue of $1M and EBITDA of ($22M).
Longeveron expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $1M | XXX | $1M | XXX | XXX | XXX |
| Gross Profit | $755K | XXX | $803K | XXX | XXX | XXX |
| Gross Margin | 71% | XXX | 67% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($22M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (1840%) | XXX | XXX | XXX |
| EBIT Margin | (2243%) | XXX | (1942%) | XXX | XXX | XXX |
| Net Profit | ($24M) | XXX | ($23M) | XXX | XXX | XXX |
| Net Margin | (2210%) | XXX | (1894%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Longeveron Stock Performance
Longeveron has current market cap of $32M, and enterprise value of $28M.
Market Cap Evolution
Longeveron's stock price is $1.09.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $28M | $32M | -0.9% | XXX | XXX | XXX | $-0.78 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialLongeveron Valuation Multiples
Longeveron trades at 26.3x EV/Revenue multiple, and (1.3x) EV/EBITDA.
EV / Revenue (LTM)
Longeveron Financial Valuation Multiples
As of April 18, 2026, Longeveron has market cap of $32M and EV of $28M.
Equity research analysts estimate Longeveron's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Longeveron has a P/E ratio of (1.4x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $32M | XXX | $32M | XXX | XXX | XXX |
| EV (current) | $28M | XXX | $28M | XXX | XXX | XXX |
| EV/Revenue | 26.3x | XXX | 23.4x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (1.3x) | XXX | XXX | XXX |
| EV/EBIT | (1.2x) | XXX | (1.2x) | XXX | XXX | XXX |
| EV/Gross Profit | 37.2x | XXX | 35.0x | XXX | XXX | XXX |
| P/E | (1.4x) | XXX | (1.4x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Longeveron Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Longeveron Margins & Growth Rates
Longeveron's revenue in the last 12 month declined by (27%).
Longeveron's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.9M for the same period.
Longeveron Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (27%) | XXX | (37%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (1840%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 42% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.9M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 1165% | XXX | 1005% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 1139% | XXX | 1004% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 2009% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Longeveron Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Longeveron | XXX | XXX | XXX | XXX | XXX | XXX |
| BioXcel Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Tvardi Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Lipum | XXX | XXX | XXX | XXX | XXX | XXX |
| Outlook Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Marinomed Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Longeveron M&A Activity
Longeveron acquired XXX companies to date.
Last acquisition by Longeveron was on XXXXXXXX, XXXXX. Longeveron acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Longeveron
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialLongeveron Investment Activity
Longeveron invested in XXX companies to date.
Longeveron made its latest investment on XXXXXXXX, XXXXX. Longeveron invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Longeveron
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Longeveron
| When was Longeveron founded? | Longeveron was founded in 2014. |
| Where is Longeveron headquartered? | Longeveron is headquartered in United States. |
| How many employees does Longeveron have? | As of today, Longeveron has over 26 employees. |
| Who is the CEO of Longeveron? | Longeveron's CEO is Stephen H. Willard. |
| Is Longeveron publicly listed? | Yes, Longeveron is a public company listed on Nasdaq. |
| What is the stock symbol of Longeveron? | Longeveron trades under LGVN ticker. |
| When did Longeveron go public? | Longeveron went public in 2021. |
| Who are competitors of Longeveron? | Longeveron main competitors are BioXcel Therapeutics, Tvardi Therapeutics, Lipum, Outlook Therapeutics. |
| What is the current market cap of Longeveron? | Longeveron's current market cap is $32M. |
| What is the current revenue of Longeveron? | Longeveron's last 12 months revenue is $1M. |
| What is the current revenue growth of Longeveron? | Longeveron revenue growth (NTM/LTM) is (27%). |
| What is the current EV/Revenue multiple of Longeveron? | Current revenue multiple of Longeveron is 26.3x. |
| Is Longeveron profitable? | No, Longeveron is not profitable. |
| What is the current net income of Longeveron? | Longeveron's last 12 months net income is ($24M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.